Sanofi-aventis announced today that it is a partner in a new multidisciplinary atrial fibrillation research consortium, the "European Network for Translational research in Atrial Fibrillation" (EUTRAF), which has been awarded a EUR12 million grant to engage in atrial fibrillation (AF) research. The European consortium is commencing a five-year research project with the objectives of providing highly interactive research with a variety of expertise to improve management of AF including diagnosis, prevention and treatment.
"Sanofi-aventis is committed to further advancing AF patient care and delighted to do so in collaboration with a network of highly respected scientific institutions and recognised clinical experts in the field of AF," said Marc Cluzel MD, PhD, Executive Vice President, Research and Development, sanofi-aventis. "We are proud to provide sanofi-aventis R&D expertise and to contribute new candidate molecules to the network. Sanofi-aventis' pioneering research in AF spans several decades and has led to innovations such as amiodarone, and dronedarone."
No comments:
Post a Comment